Lung Cancer | Clinical

November 21, 2020

During a Targeted Oncology Case Based Peer Perspectives event, John Heymach, MD, PhD, professor and Chair, David Bruton Jr Chair in Cancer Research. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discussed the guidelines and therapeutic option for stage III non–small cell lung cancer, based on a case of a 66-year-old patient.

November 20, 2020

The FDA has approved an additional dosing option for the approved indications of durvalumab at a 1500-mg fixed dose administered every 4 weeks.

November 20, 2020

During Lung Cancer Awareness Month, David Spigel, MD, shared his insights on the evolving treatment paradigm in lung cancer and how the latest advances have impacted his treatment decisions for patients with lung cancer.

November 18, 2020

Patients of color who were diagnosed with lung cancer were associated with worse outcomes compared with Caucasian patients, according to findings from the 3rd Annual “State of Lung Cancer” Report by the American Lung Association.

November 17, 2020

The primary end point of overall survival with tislelizumab compared with docetaxel as the second- or third-line treatment of patients with locally advanced or metastatic non–small cell lung cancer who progressed on previous platinum-based chemotherapy.

November 16, 2020

Dramatic improvements in efficacy outcomes for patients with non–small cell lung cancer have been a reason for celebration over the last decade, as FDA approvals of immunotherapy-plus-chemotherapy combinations as well as oncogenic-targeting drugs have transformed the treatment landscape.

November 16, 2020

Dr David Spigel provides information on the PACIFIC trial, including the 4-year update.

November 10, 2020

The phase 3 KEYNOTE-598 study of pembrolizumab plus ipilimumab in a population of patients with metastatic non–small cell lung cancer has been discontinued for futility.

November 09, 2020

Alexander Drilon, MD, chief of Early Drug Development Service at Memorial Sloan Kettering Cancer Center in New York, discussed each of the recently approved agents used for the treatment of these tumors and presented a review of the data at the 15th Annual New York Lung Cancer Symposium.

November 09, 2020

As the field of lung cancers continues to lean further into the precision medicine era, KRAS G12C has become an emerging actionable target for which multiple therapies are under development, said Bob T. Li, MD.